Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can push T cells to burn through their energy while producing cancer-killing proteins. In animal and laboratory studies, blocking MEK helped the cells conserve energy, survive longer, and remain active even in the harsh environment around tumors.
Cancer immunotherapy can lose its punch when tumor-fighting T cells become exhausted, but researchers may have found a way to keep them going longer. Scientists at Memorial Sloan Kettering Cancer Center identified a signaling molecule called MEK that can push T cells to burn through their energy while producing cancer-killing proteins. In animal and laboratory studies, blocking MEK helped the cells conserve energy, survive longer, and remain active even in the harsh environment around tumors.
Source: ScienceDaily
